AI Stock Memo: DOCS - Doximity - RankAlpha

DOCS

Rating neutralAI MemoPost-earnings T+3

Doximity

As of 2026-05-16/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Post-earnings guidance reset reframed the story • 2026-05-13

Expected move: -8%

Biggest risk

The post-print problem is not the quarter itself but the outlook. FY27 revenue guidance implies only about 4% growth at the midpoint and adjusted EBITDA is guided down y/y [#8-K-2026-05-13]. BTIG downgraded the stock on May 14, 2026, and reported estimate cuts and multiple target reductions point to weaker visibility, softer pharma spending, and concern that AI investment payback will take time.

Invalidation

Break below $15 or thesis failure.

What would change my mind?

The primary source still shows a real franchise: FY26 revenue grew 13%, operating cash flow grew 19%, free cash flow grew 19%, and platform engagement hit new highs with over 800,000 workflow-tool prescribers and nearly half using clinical AI in Q4 [#8-K-2026-05-13]. If the FY27 guide proves conservative, the reset could create room for positive revisions.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-16

Base target

$21

p=45%

Bull target

$25

p=25%

Bear target

$15

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 FY27 print is the first test of the new floor
AI and workflow partnerships need to convert into durable monetization
The primary source still shows a real franchise: FY26 revenue grew 13%, operating cash flow grew 19%, free cash flow grew 19%, and platform engagement hit new highs with over 800,000 workflow-tool prescribers and nearly half using clinical AI in Q4 [#8-K-2026-05-13].

BearKey bullets

Competitive risk: analyst commentary flagged growing overlap with AI-native tools and larger healthcare software platforms such as Veeva-style workflows.
Demand visibility risk: post-earnings coverage cited softer digital pharma demand, shorter contract duration, and policy/macro uncertainty affecting customer commitments.
FY27 guidance reset: revenue of $664M-$676M and adjusted EBITDA of $323M-$335M came in below outside expectations, keeping near-term estimate risk elevated.

WatchKey bullets

Post-earnings guidance reset reframed the story

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $21 (p=45%)

Bull/Bear spread: +12% / -35%

Vs latest close: Bull +12% · Base -8% · Bear -35%

Scenario probabilities

Bull Target: $25 (p=25%)Base Target: $21 (p=45%)Bear Target: $15 (p=30%)

Commentary

Post-earnings tone is negative and revision-driven. The May 13, 2026 release showed solid cash generation and engagement, but the market focused on slower FY27 growth and lower EBITDA guidance. By May 14-15, 2026, BTIG had downgraded the stock and several firms had cut targets, while the shares had reset to $18.97 by the May 15 close. The packet has no usable social-coverage signal, so confidence should stay moderate rather than aggressive.

As of 2026-05-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 FY27 print is the first test of the new floor
AI and workflow partnerships need to convert into durable monetization

Scenarios

Bull Target (Scenario probability)

$25 / p=25% prob

Base Target (Scenario probability)

$21 / p=45% prob

Bear Target (Scenario probability)

$15 / p=30% prob

Price $22 as of 2026-07-15

Nearest Scenario: Base (∆ 8%)

Targets vs latest close: Bull +12% · Base -8% · Bear -35%

Sentiment & Exposure

News Sentiment (30d)

-0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-13
Post-earnings guidance reset reframed the story
The May 13, 2026 earnings release showed Q4 revenue of $145.4M, up 5% y/y, but FY27 guidance reset lower to $664M-$676M revenue and $323M-$335M adjusted EBITDA, while management highlighted record workflow engagement and accelerating clinical AI usage [#8-K-2026-05-13].
Prob 90.00% • Move -12.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Q1 FY27 print is the first test of the new floor
2026-08-07
Management guided June-quarter revenue to $151M-$152M and adjusted EBITDA to $68.5M-$69.5M [#8-K-2026-05-13]. A clean beat could stabilize sentiment after the reset, while another soft demand read would reinforce the de-rating.
Prob 55% • Move 14% • Priced-in 45%

Long-term Catalysts

Months to a year

AI and workflow partnerships need to convert into durable monetization
2026-11-15
Management cited over 800,000 active prescribers using workflow tools in Q4, nearly half using clinical AI, plus new Aledade and Photon partnerships [#8-K-2026-05-13]. The longer-duration upside case depends on those usage gains showing up in renewed growth rather than just higher investment.
Prob 40% • Move 25% • Priced-in 30%

Risks

Competitive risk: analyst commentary flagged growing overlap with AI-native tools and larger healthcare software platforms such as Veeva-style workflows.
Demand visibility risk: post-earnings coverage cited softer digital pharma demand, shorter contract duration, and policy/macro uncertainty affecting customer commitments.
FY27 guidance reset: revenue of $664M-$676M and adjusted EBITDA of $323M-$335M came in below outside expectations, keeping near-term estimate risk elevated.
Leadership-transition risk: Doximity appointed a new CFO and new president effective May 13, 2026, during a period of guidance reset and heavier execution demands [#8-K-2026-05-13].
Margin risk from the AI push: management is leaning into an AI investment year, which raises the chance that revenue lags incremental spending and stock-based compensation pressure.

Peers

Symbol	Summary
IRTC	iRhythm is the closest digital-health style comp in the packet, but its cardiac-monitoring model is still materially different; useful mainly for sentiment on healthcare-tech execution rather than direct valuation.
ALHC	Alignment Healthcare is a loose same-cap healthcare-services comp; it highlights that DOCS is being punished for forward growth visibility despite stronger current margins.
CON	Concentra is another loose healthcare-services comp by size, but its clinic footprint and payer/provider exposure differ sharply, limiting direct read-through.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-16